Moderna Raises 2026 Outlook After Strong Q3 Profit
Moderna raised its full-year 2026 revenue growth target to 15–25% after beating third-quarter earnings expectations and returning to profitability.
Topic
mRNA vaccines
The latest mRNA vaccines news, explained clearly: what happened, why it matters and what comes next. Every NewsClearly story on mRNA vaccines, newest first.
1 story